Showing 2680 results
-
Press Release /Solides Wachstum (kWk[1]) im dritten Quartal beim Umsatz, operativen Kernergebnis und Kerngewinn pro Aktie der fortzuführenden Geschäftsbereiche[2]: Der Nettoumsatz beläuft sich auf USD 12,3…
-
Press Release /Croissance solide (tcc[1]), au T3, des ventes, du résultat opérationnel core et du BPA core des activités poursuivies[2] Chiffre d'affaires net d'USD 12,3 milliards (-6%, +6% tcc) Résultat…
-
Press Release /Solid growth (cc[1]) in Q3 sales, core operating income, core EPS for continuing operations[2] Net sales were USD 12.3 billion (-6%, +6% cc) Operating income was USD 2.2 billion (-18%, +2% cc) Core…
-
Press Release /Community-based Hypertension Improvement Project (ComHIP) is an innovative healthcare model designed to improve hypertension management and control Screening and treatment is shifted to the…
-
Press Release /Nominees for election by shareholders at Annual General Meeting (AGM) in February 2016 Basel, November 4, 2015 - The Novartis Board of Directors announced today, that it is nominating Ms.…
-
Press Release /New x-ray assessment data, from a sub-study, showed no progression of joint structural damage in the majority of patients with psoriatic arthritis over two years[1] Psoriatic arthritis patients on…
-
Press Release /A sub-study showed up to 80% of ankylosing spondylitis (AS) patients treated with Cosentyx had no radiographic progression in the spine over two years[1] Cosentyx demonstrated a sustained…
-
Press Release /Nearly 65% of eyes treated with personalized topography-guided LASIK experienced 20/16 vision or better[1] in clinical study Alcon is the first refractive laser manufacturer to receive FDA…
-
Press Release /Sandoz continues to advance its biosimilars program: Regulatory submission for Sandoz' proposed biosimilar pegfilgrastim accepted by the FDA Sandoz demonstrates commitment to oncology by seeking…
-
Press Release /Ultibro® Breezhaler® met primary endpoint and demonstrated superiority to Seretide® in reducing COPD exacerbations during 52 weeks of treatment First large-scale study to confirm Ultibro…